Cardiology Letters 2020, 29(5):279-283
Comment on 2019 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
- 1 Klinika kardiológie a angiológie LF SZU a NÚSCH, a. s., Bratislava
- 2 I. interná klinika LF UK a UN Bratislava
- 3 Fakulta zdravotníckych vied UCM Trnava, Slovenská republika
Published: May 1, 2020 Show citation
References
- Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016;118:1340-1347.
Go to original source... - Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 2014;311:1117-1124. Go to original source...
- Murphy N, Broadhurst DI, Khashan AS, et al. Gestation-specific D-dimer reference ranges: a cross-sectional study. BJOG 2015;122:395-400. Go to original source...
- Ercan S, Ozkan S, Yucel N, et al. Establishing reference intervals for D-dimer to trimesters. J Matern Fetal Neonatal Med 2015;28:983-987. Go to original source...
- Gašpar Ľ, Makovník M, Gavorník P, et al. Riziká akútnej pľúcnej embólie u pacientov interného oddelenia. Vask med 2012;4:4749.
- Belicová M, Sadloňová J, Mokáň M. Pľúcna embólia, výskyt, diagnostika a liečba v 10-ročnom období v spádovej nemocnici. Interná med. 2008;8:441-447.
- Palacka P, Dostálová K, Štvrtinová V. Prevencia a liečba venózneho tromboembolizmu v onkológii. In: Štvrtinová V, et al. Venózny tromboembolizmus. Bratislava: SAP-Slovak Academic Press; 2018:75-93.
- Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:20172023. Go to original source...
- Raskob GE, van Es N, Verhamme P, et al. on behalf of the Hokusai VTE Cancer Investigators: Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-624. Go to original source...
- Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808. Go to original source...
- Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-1297. Go to original source...
- Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365-1371. Go to original source...
- Bohacekova M, Kaldararova M, Valkovicova T, et al. Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification? Bratisl Med J 2016;117:577-582. Go to original source...
- Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:325-331. Go to original source...
- Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-1981. Go to original source...
- Hoeper MM, Gomez Sanchez MA, Humbert M, et al. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, Nov 2020, DOI: https://doi.org/10.1016/j.rmed.2020.106241 Go to original source...
- Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016;133:859-871. Go to original source...